Marques de Marino Pablo, Abu Jiries Melad, Tesinsky Pavel, Ibraheem Anas, Katsargyris Athanasios, Verhoeven Eric L
Department of Vascular and Endovascular Surgery, General Hospital Nuremberg, Paracelsus Medical University, 90471 Nuremberg, Germany.
J Clin Med. 2022 Sep 23;11(19):5596. doi: 10.3390/jcm11195596.
This study aims to assess the mid-term results of fenestrated endovascular aneurysm repair (FEVAR) for the treatment of proximal aortic pathology after previous open surgical repair (OSR). All patients with a previous history of OSR of an abdominal aortic aneurysm undergoing a FEVAR procedure between October 2010 and November 2021 were included. The endpoints of the study were technical success, mortality, target vessel patency and reinterventions during follow-up. Thirty-five patients (34 male, mean age 72.9 ± 7 years) were included. The median interval from the primary surgery to the FEVAR procedure was 136 months (range 47-261). The indication for treatment was a para-anastomotic aneurysm in 18 (51%) patients and a true aneurysm due to progression of disease in 17 (49%) patients. Technical success was achieved in 33 (94%) patients. There was one (3%) early death due to postoperative bleeding from a renal artery. Estimated survival at 12, 24 and 36 months was 89.1% ± 6%, 84.4% ± 7.3% and 84.4% ± 7.3%, respectively. There was no aneurysm-related mortality. One (3%) target vessel occluded during follow-up and three (9%) patients underwent late reinterventions. In conclusion, FEVAR is a safe and effective alternative for the endovascular treatment of para-anastomotic aneurysms/pseudoaneurysms after OSR showing high technical success, low mortality and morbidity, and good mid-term outcomes.
本研究旨在评估开窗式血管腔内动脉瘤修复术(FEVAR)治疗既往开放性手术修复(OSR)后近端主动脉病变的中期结果。纳入2010年10月至2021年11月期间接受FEVAR手术且既往有腹主动脉瘤OSR病史的所有患者。研究终点为技术成功率、死亡率、靶血管通畅率及随访期间的再次干预情况。共纳入35例患者(34例男性,平均年龄72.9±7岁)。从初次手术到FEVAR手术的中位间隔时间为136个月(范围47 - 261个月)。治疗指征为18例(51%)患者的吻合口旁动脉瘤和17例(49%)患者因疾病进展导致的真性动脉瘤。33例(94%)患者获得技术成功。有1例(3%)患者因肾动脉术后出血早期死亡。12个月、24个月和36个月的预计生存率分别为89.1%±6%、84.4%±7.3%和84.4%±7.3%。无动脉瘤相关死亡。随访期间1例(3%)靶血管闭塞,3例(9%)患者接受了晚期再次干预。总之,FEVAR是OSR后吻合口旁动脉瘤/假性动脉瘤血管腔内治疗的一种安全有效的替代方法,技术成功率高,死亡率和发病率低,中期结果良好。